HRP20212023T1 - Modulokini temeljeni na il-15 i il-15ralpha sushi domeni - Google Patents

Modulokini temeljeni na il-15 i il-15ralpha sushi domeni Download PDF

Info

Publication number
HRP20212023T1
HRP20212023T1 HRP20212023TT HRP20212023T HRP20212023T1 HR P20212023 T1 HRP20212023 T1 HR P20212023T1 HR P20212023T T HRP20212023T T HR P20212023TT HR P20212023 T HRP20212023 T HR P20212023T HR P20212023 T1 HRP20212023 T1 HR P20212023T1
Authority
HR
Croatia
Prior art keywords
seq
amino acid
acid sequence
immunocytokine
antagonists
Prior art date
Application number
HRP20212023TT
Other languages
English (en)
Inventor
Alain GEY
Eric Tartour
David Bechard
Original Assignee
Cytune Pharma
Université de Paris
Assistance Publique Hôpitaux De Paris
Institut National De La Santé Et De La Recherche Médicale (Inserm)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48953308&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20212023(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cytune Pharma, Université de Paris, Assistance Publique Hôpitaux De Paris, Institut National De La Santé Et De La Recherche Médicale (Inserm) filed Critical Cytune Pharma
Publication of HRP20212023T1 publication Critical patent/HRP20212023T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Image Processing (AREA)

Claims (14)

1. Imunocitokin koji sadrži: a) konjugat, i b) imunomodulatorno antitijelo ili njegov fragment sposoban reagirati s istim antigenom kao njegov pandan antitijela, izravno ili neizravno povezano kovalencijom na navedeni konjugat, pri čemu navedeni konjugat sadrži: (i) polipeptid koji sadrži aminokiselinsku sekvencu interleukina-15 ili njegov derivat, pri čemu derivat ima aminokiselinsku sekvencu s postotkom identiteta od najmanje 92,5 % sa aminokiselinskom sekvencom odabranom iz skupine koju čine SEQ ID n°:1, SEQ ID n°:2, SEQ ID n°:3, i (ii) polipeptid koji sadrži aminokiselinsku sekvencu sushi domene IL-15Rα ili njegovog derivata, pri čemu derivat ima aminokiselinsku sekvencu koja ima postotak identiteta od najmanje 92% sa aminokiselinskom sekvencom odabranom iz skupine koju čine SEQ ID n°:4, SEQ ID n°:5, SEQ ID n°:6, SEQ ID n°:7, SEQ ID n°:8 i SEQ ID n°:9; i pri čemu navedeno imunomodulatorno antitijelo ili njegov fragment inhibira imunosupresivni receptor ili stimulira ko-stimulacijski receptor.
2. Imunocitokin prema zahtjevu 1, naznačen time što imunomodulatorno antitijelo ili njegov fragment a. inhibira imunosupresivni receptor i odabran je u skupini koja sadrži CTL-A4 antagoniste, inhibitorne KIRs antagoniste, BTLA antagoniste, LAG3 antagoniste, HAVCR2 antagoniste, ADORA2A antagoniste i PD-1 antagoniste, ili b. stimulira ko-stimulacijski receptor i odabran je u skupini koja sadrži CD40 agoniste, CD137 agoniste, CD134 agoniste i TNFRSF18 agoniste.
3. Imunocitokin prema zahtjevu 1 ili zahtjevu 2, naznačen time što (i) navedeni derivat interleukina 15 ima aminokiselinsku sekvencu koja ima postotak identiteta od najmanje 96%, poželjno od najmanje 98.5% ili još poželjnije od najmanje 99% sa aminokiselinskom sekvencom odabranom iz skupine koju čine SEQ ID n°:1, SEQ ID n°:2, SEQ ID n°:3; i/ili (ii) navedeni derivat sushi domene IL-15Rα ima aminokiselinsku sekvencu s postotkom identiteta od najmanje 96%, ili poželjno od najmanje 98% sa aminokiselinskom sekvencom odabranom iz skupine koju čine SEQ ID n°:4, SEQ ID n°:5, SEQ ID n°:6, SEQ ID n°:7, SEQ ID n°:8 i SEQ ID n°:9.
4. Imunocitokin prema bilo kojem od zahtjeva 1 do 3, naznačen time što je navedeno imunomodulatorno antitijelo ili njegov fragment koji inhibira imunosupresivni receptor odabran između a) CTL-A4 antagonista, poželjno ipilimumab ili ticilimumab, b) inhibitorni KIRs antagonista, poželjno 1-7F9, ili c) PD-1 antagonista, poželjno anti-PD-1 antitijela i anti-PD-L1 antitijela, poželjnije nivolumab, Merck 3745 ili CT-01 1 (također poznat kao hBAT).
5. Imunocitokin prema bilo kojem zahtjevu 1 do 4, naznačen time što a) polipeptidi i) i ii) konjugata su kovalentno povezani u fuzijski protein; i b) navedeni konjugat i antitijelo ili njegov fragment su kovalentno povezani u fuzijski protein.
6. Imunocitokin prema bilo kojem od zahtjeva 1 do 5, naznačen time što (i) interleukin-15 ima aminokiselinsku sekvencu SEQ ID n°1; i/ili (ii) sushi domena IL-15Rα ima aminokiselinsku sekvencu SEQ ID n°4.
7. Imunocitokin prema bilo kojem od zahtjeva 1 do 6, naznačen time što polipeptid (ii) koji sadrži aminokiselinsku sekvencu sushi domene IL-15Rα ili njegovih derivata ima aminokiselinsku sekvencu SEQ ID n°12.
8. Imunocitokin prema zahtjevu 7, naznačen time što navedeni konjugat sadrži aminokiselinsku sekvencu interleukina-15 ili njegovih derivata na C-terminalnom položaju u odnosu na aminokiselinsku sekvencu sushi domene IL-15Rα ili njegovih derivata, i gdje aminokiselinska sekvenca konjugata je na C-terminalnom položaju u odnosu na aminokiselinsku sekvencu antitijela ili njegovog fragmenta.
9. Nukleinska kiselina koja kodira imunocitokin kako je definirano u bilo kojem od zahtjeva 1 do 8.
10. Vektor koji sadrži nukleinsku kiselinu kako je definirana u zahtjevu 9.
11. Stanica domaćin genetski konstruirana s nukleinskom kiselinom prema zahtjevu 9 ili vektorom prema zahtjevu 10, poželjno navedena stanica domaćin je životinjska stanica i poželjnije stanica domaćina je CHO stanica.
12. Farmaceutski pripravak koji sadrži imunocitokin prema bilo kojem od zahtjeva 1 do 8, nukleinsku kiselinu prema zahtjevu 9, ili vektor prema zahtjevu 10, i izborno farmaceutski prihvatljiv nosač.
13. Imunocitokin prema bilo kojem od zahtjeva 1 do 8, nukleinska kiselina prema zahtjevu 9, vektor prema zahtjevu 10 ili farmaceutski pripravak prema zahtjevu 12 za uporabu u liječenju raka, izborno pri čemu je rak uznapredovali rak, poželjno karcinom ili rak pluća, poželjnije karcinom bubrežnih stanica (RCC).
14. Imunocitokin prema bilo kojem od zahtjeva 1 do 8, nukleinska kiselina prema zahtjevu 9, ili vektor prema zahtjevu 10 za uporabu u kombinaciji s terapeutskim sredstvom, poželjno sredstvom protiv raka, za istovremenu, odvojenu ili sekvencijalnu uporabu za liječenje raka kod subjekta.
HRP20212023TT 2013-08-08 2014-08-08 Modulokini temeljeni na il-15 i il-15ralpha sushi domeni HRP20212023T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13003963 2013-08-08
EP18177685.7A EP3444271B1 (en) 2013-08-08 2014-08-08 Il-15 and il-15ralpha sushi domain based modulokines

Publications (1)

Publication Number Publication Date
HRP20212023T1 true HRP20212023T1 (hr) 2022-04-01

Family

ID=48953308

Family Applications (3)

Application Number Title Priority Date Filing Date
HRP20212023TT HRP20212023T1 (hr) 2013-08-08 2014-08-08 Modulokini temeljeni na il-15 i il-15ralpha sushi domeni
HRP20231437TT HRP20231437T1 (hr) 2013-08-08 2014-08-08 Il-15 i il-15ralpha sushi domena na temelju modulokina
HRP20181472TT HRP20181472T1 (hr) 2013-08-08 2018-09-13 Il-15 i il-15r-alpha "sushi domain" modulokini

Family Applications After (2)

Application Number Title Priority Date Filing Date
HRP20231437TT HRP20231437T1 (hr) 2013-08-08 2014-08-08 Il-15 i il-15ralpha sushi domena na temelju modulokina
HRP20181472TT HRP20181472T1 (hr) 2013-08-08 2018-09-13 Il-15 i il-15r-alpha "sushi domain" modulokini

Country Status (18)

Country Link
US (2) US11273204B2 (hr)
EP (4) EP4269441A3 (hr)
JP (2) JP6649254B2 (hr)
KR (2) KR102564207B1 (hr)
CN (1) CN105612175B (hr)
AU (1) AU2014304931B2 (hr)
BR (1) BR112016002614B8 (hr)
CA (1) CA2919725C (hr)
DK (2) DK3030575T3 (hr)
EA (1) EA031080B1 (hr)
ES (3) ES2690046T3 (hr)
HR (3) HRP20212023T1 (hr)
HU (2) HUE057598T2 (hr)
MX (1) MX2016001555A (hr)
PL (3) PL3995507T3 (hr)
PT (2) PT3444271T (hr)
SI (2) SI3444271T1 (hr)
WO (1) WO2015018528A1 (hr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147379A (en) 2005-12-02 2012-11-30 Sinai School Medicine Chimeric viruses presenting non-native surface proteins and uses thereof
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
EP3620473A1 (en) 2013-01-14 2020-03-11 Xencor, Inc. Novel heterodimeric proteins
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
SG10201802982WA (en) 2013-03-14 2018-06-28 Icahn School Med Mount Sinai Newcastle disease viruses and uses thereof
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
CA2906927C (en) 2013-03-15 2021-07-13 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
JP6857498B2 (ja) 2014-02-27 2021-04-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 癌を処置するための併用方法
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
BR112016020919A2 (pt) 2014-03-12 2018-01-23 Yeda Res & Dev redução dos níveis ou da atividade sistêmica de células t regulatórias para o tratamento de doença e lesão do snc
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US9394365B1 (en) 2014-03-12 2016-07-19 Yeda Research And Development Co., Ltd Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
ME03666B (me) 2014-03-28 2020-10-20 Xencor Inc Bispecifična antitela koja se vezuju za cd38 i cd3
EP3223845B1 (en) 2014-11-26 2021-05-19 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd20
KR20170084327A (ko) 2014-11-26 2017-07-19 젠코어 인코포레이티드 Cd3 및 cd38에 결합하는 이형이량체 항체
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016141387A1 (en) 2015-03-05 2016-09-09 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US20180155439A1 (en) * 2015-06-10 2018-06-07 Emory University Compositions and Conjugates Comprising an Interleukin and Polypeptides That Specifically Bind TGF-beta
US10858452B2 (en) 2015-09-16 2020-12-08 Insitut National de la Sante et de la Recherche Medicale (INSERM) Specific interleukin-15 (IL-15) antagonist polypeptide and uses thereof for the treatment of inflammatory and auto-immune diseases
CR20180161A (es) 2015-10-02 2018-05-25 Hoffmann La Roche Anticuerpos biespecíficos para pd1 y tim3
JP7058219B2 (ja) 2015-12-07 2022-04-21 ゼンコア インコーポレイテッド Ｃｄ３及びｐｓｍａに結合するヘテロ二量体抗体
US11661455B2 (en) 2016-02-05 2023-05-30 Orionis Biosciences BV Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety
WO2017134306A1 (en) 2016-02-05 2017-08-10 Orionis Biosciences Nv Cd8 binding agents
WO2017158436A1 (en) * 2016-03-17 2017-09-21 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
CA3024509A1 (en) 2016-05-18 2017-11-23 Modernatx, Inc. Mrna combination therapy for the treatment of cancer
AU2017283480A1 (en) 2016-06-13 2019-01-24 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
RU2022104399A (ru) 2016-06-14 2022-05-05 Ксенкор, Инк. Биспецифические антитела-ингибиторы контрольных точек
US10316088B2 (en) 2016-06-28 2019-06-11 Xencor, Inc. Heterodimeric antibodies that bind somatostatin receptor 2
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR102562519B1 (ko) * 2016-10-14 2023-08-02 젠코어 인코포레이티드 IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
PL3606946T3 (pl) * 2017-04-03 2022-11-28 F. Hoffmann-La Roche Ag Immunokoniugaty przeciwciała anty-PD-1 ze zmutowaną IL-2 lub z IL-15
BR112019019821A2 (pt) 2017-04-05 2020-04-22 Hoffmann La Roche anticorpo biespecífico, polinucleotídeo, célula hospedeira procariótica ou eucariótica, métodos de produção do anticorpo biespecífico, de tratamento de um indivíduo que tem câncer ou uma infecção viral crônica e de inibição do crescimento de células de tumor, composição farmacêutica e uso do anticorpo biespecífico
MA49517A (fr) 2017-06-30 2020-05-06 Xencor Inc Protéines de fusion fc hétérodimères ciblées contenant il-15/il-15ra et domaines de liaison à l'antigène
EP3665201A4 (en) 2017-08-09 2021-06-02 Orionis Biosciences, Inc. CD8 BINDERS
WO2019032663A1 (en) 2017-08-09 2019-02-14 Orionis Biosciences Inc. PD-1 AND PD-L1 BINDING AGENTS
EP3678701A4 (en) 2017-09-05 2021-12-01 Torque Therapeutics, Inc. THERAPEUTIC PROTEIN COMPOSITIONS AND METHOD FOR MANUFACTURING AND USING THEREOF
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR20200085828A (ko) 2017-11-08 2020-07-15 젠코어 인코포레이티드 신규의 항-pd-1 서열을 사용한 이중특이적 및 단일특이적 항체
MX2020006322A (es) 2017-12-19 2020-09-18 Xencor Inc Proteinas de fusion il-2 fc modificadas.
TW201938196A (zh) * 2018-01-18 2019-10-01 美商南特生物科學股份有限公司 融合蛋白擴展
RU2020128440A (ru) 2018-02-28 2022-03-28 Пфайзер Инк. Варианты il-15 и их применения
AU2019247415A1 (en) 2018-04-04 2020-10-22 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CA3097625A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Il-15/il-15ra heterodimeric fc fusion proteins and uses thereof
WO2019204665A1 (en) * 2018-04-18 2019-10-24 Xencor, Inc. Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
CN112437777A (zh) 2018-04-18 2021-03-02 Xencor股份有限公司 包含IL-15/IL-15RA Fc融合蛋白和TIM-3抗原结合结构域的靶向TIM-3的异源二聚体融合蛋白
EP3781597A1 (en) * 2018-04-18 2021-02-24 Xencor, Inc. Lag-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and lag-3 antigen binding domains
CA3115096A1 (en) 2018-10-03 2020-04-09 Xencor, Inc. Il-12 heterodimeric fc-fusion proteins
BR112021006783A2 (pt) 2018-10-12 2021-07-13 Xencor, Inc. proteína de fusão fc heterodimérica de il-15/r¿ direcionada, composição de ácido nucleico, composição de vetor de expressão, célula hospedeira, e, métodos de produção da proteína de fusão fc heterodimérica de il-15/r¿ direcionada e de tratamento de um câncer.
CN113438961A (zh) * 2018-12-20 2021-09-24 Xencor股份有限公司 含有IL-15/IL-15Rα和NKG2D抗原结合结构域的靶向异二聚体Fc融合蛋白
US11472890B2 (en) 2019-03-01 2022-10-18 Xencor, Inc. Heterodimeric antibodies that bind ENPP3 and CD3
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease
CA3136241A1 (en) 2019-05-20 2020-11-26 Ulrich Moebius Il-2/il-15r.beta.y agonist dosing regimens for treating cancer or infectious diseases
CA3147767A1 (en) * 2019-08-17 2021-02-25 Igm Biosciences, Inc. Multimeric bispecific anti-cd123 binding molecules and uses thereof
CN110478474B (zh) * 2019-08-21 2020-06-02 启辰生生物科技(珠海)有限公司 免疫调节剂、疫苗、细胞及应用
CN116574183A (zh) * 2019-08-22 2023-08-11 盛禾(中国)生物制药有限公司 多功能抗体、其制备及其用途
US20220332780A1 (en) 2019-09-10 2022-10-20 Obsidian Therapeutics, Inc. Ca2-il15 fusion proteins for tunable regulation
RU2753282C2 (ru) 2019-09-19 2021-08-12 Закрытое Акционерное Общество "Биокад" ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
CN114787181A (zh) * 2019-11-21 2022-07-22 Inserm(法国国家健康医学研究院) 用抗pd-1/il-15免疫细胞因子靶向pd-1的新型免疫疗法
CN110804588B (zh) * 2019-11-22 2020-09-01 启辰生生物科技(珠海)有限公司 用于协同改善t淋巴细胞性质的组合物及其应用
EP3889183A1 (en) * 2020-04-01 2021-10-06 Pierre Fabre Medicament A protein complex comprising an immunocytokine
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
EP4200332A1 (en) 2020-08-19 2023-06-28 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
EP4208476A1 (en) * 2020-09-01 2023-07-12 Wuxi Biologics Ireland Limited Long-acting il-15 and uses thereof
US20230390361A1 (en) 2020-10-26 2023-12-07 Cytune Pharma Il-2/il-15r-beta-gamma agonist for treating squamous cell carcinoma
WO2022090202A1 (en) 2020-10-26 2022-05-05 Cytune Pharma IL-2/IL-15RBβү AGONIST FOR TREATING NON-MELANOMA SKIN CANCER
CA3212665A1 (en) 2021-03-09 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cldn6
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
US20230151095A1 (en) 2021-11-12 2023-05-18 Xencor, Inc. Bispecific antibodies that bind to b7h3 and nkg2d
WO2024102636A1 (en) 2022-11-07 2024-05-16 Xencor, Inc. Bispecific antibodies that bind to b7h3 and mica/b

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5997856A (en) 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5073627A (en) 1989-08-22 1991-12-17 Immunex Corporation Fusion proteins comprising GM-CSF and IL-3
US5108910A (en) 1989-08-22 1992-04-28 Immunex Corporation DNA sequences encoding fusion proteins comprising GM-CSF and IL-3
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
US6051227A (en) 1995-07-25 2000-04-18 The Regents Of The University Of California, Office Of Technology Transfer Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
US5855887A (en) 1995-07-25 1999-01-05 The Regents Of The University Of California Blockade of lymphocyte down-regulation associated with CTLA-4 signaling
US5811097A (en) 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
JP2001523958A (ja) 1997-03-21 2001-11-27 ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド 免疫療法のｃｔｌａ−４結合ペプチド
RS51309B (sr) 1998-12-23 2010-12-31 Pfizer Inc. Humana monoklonalna antitela za ctla-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
EE05627B1 (et) 1998-12-23 2013-02-15 Pfizer Inc. CTLA-4 vastased inimese monoklonaalsed antikehad
EP1792991A1 (en) 1999-08-24 2007-06-06 Medarex, Inc. Human CTLA-4 antibodies and their uses
IL149701A0 (en) 2001-05-23 2002-11-10 Pfizer Prod Inc Use of anti-ctla-4 antibodies
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1539237A4 (en) 2002-07-30 2006-05-24 Bristol Myers Squibb Co HUMANIZED ANTIBODIES AGAINST HUMAN 4-1BB
PL216630B1 (pl) 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
PT1707627E (pt) 2003-12-25 2013-01-24 Kyowa Hakko Kirin Co Ltd Mutante antagonista de anticorpo anti-cd40
ES2367027T3 (es) 2004-02-27 2011-10-27 Inserm (Institut National De La Santé Et De La Recherche Medicale) Sitio de unión de la il-15 para il-15ralfa y mutantes específicos de il-15 que tienen actividad agonista/antagonista.
WO2006003179A2 (en) * 2004-07-01 2006-01-12 Novo Nordisk A/S Antibodies binding to receptors kir2dl1, -2, 3 but not kir2ds4 and their therapeutic use
EP1819702A1 (en) 2004-11-29 2007-08-22 Pharmacia & Upjohn Company LLC Thiazepine oxazolidinones as antibacterial agents
ES2657443T3 (es) 2005-03-25 2018-03-05 Gitr, Inc. Anticuerpos anti-GITR y usos de los mismos
SI2439273T1 (sl) 2005-05-09 2019-05-31 Ono Pharmaceutical Co., Ltd. Človeška monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka z uporabo protiteles proti PD-1 samostojno ali v kombinaciji z ostalimi imunoterapevtiki
CA2608474C (en) 2005-05-17 2019-11-12 University Of Connecticut Compositions and methods for immunomodulation in an organism
KR100694508B1 (ko) 2005-05-24 2007-03-13 울산대학교 산학협력단 Ｈｂｂｋ４항체를 포함하는 암 질환 치료용 약학조성물및 이를 이용한 암의 면역치료 방법
CN101248089A (zh) 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
EP1777294A1 (en) 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
AR063840A1 (es) 2006-11-15 2009-02-25 Medarex Inc Anticuerpos humanos monoclonales para btla y metodos de uso
NZ578650A (en) 2006-12-27 2011-12-22 Harvard College Pd-1 and activated t-cell compositions and methods for the treatment of viral infections and tumors
ES2470772T3 (es) 2007-05-11 2014-06-24 Altor Bioscience Corporation Moléculas de fusión y variantes de IL-15
KR101586617B1 (ko) 2007-06-18 2016-01-20 머크 샤프 앤 도메 비.브이. 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
JP2010531878A (ja) 2007-06-27 2010-09-30 マリン ポリマー テクノロジーズ，インコーポレーテッド ＩＬ‐１５とＩＬ‐１５Ｒαとの複合体及びその使用
PT2851374T (pt) 2007-12-14 2017-06-20 Pfizer Moléculas de ligação ao recetor humano ox40
WO2009101611A1 (en) 2008-02-11 2009-08-20 Curetech Ltd. Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2009135031A1 (en) 2008-04-30 2009-11-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Substituted il-15
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
PE20110435A1 (es) 2008-08-25 2011-07-20 Amplimmune Inc Composiciones antagonistas del pd-1
JP2012510429A (ja) 2008-08-25 2012-05-10 アンプリミューン、インコーポレーテッド Ｐｄ−１アンタゴニストおよびその使用方法
EP2342228B1 (en) 2008-09-12 2017-09-06 Oxford University Innovation Limited Pd-1 specific antibodies and uses thereof
WO2010029435A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
SI2342226T1 (sl) 2008-09-26 2016-11-30 Dana-Farber Cancer Institute Inc. Humana protitelesa proti PD-1, PD-L1 in PD-L2 in njihove uporabe
UA109108C2 (uk) 2008-12-09 2015-07-27 Дженентек, Інк. Антитіло до pd-l1 та його застосування для посилення функції t-клітин
ES2629337T3 (es) 2009-02-09 2017-08-08 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos contra PD-1 y anticuerpos contra PD-L1 y usos de los mismos
WO2010106051A1 (en) 2009-03-17 2010-09-23 Universite De La Mediterranee Btla antibodies and uses thereof
AR077594A1 (es) 2009-07-31 2011-09-07 Organon Nv Anticuerpos completamente humanos para btla (atenuante de linfocitos b y t)
NZ714757A (en) 2009-08-14 2018-07-27 Us Gov Health & Human Services Use of il-15 to increase thymic output and to treat lymphopenia
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme ANTI-GITRANT ANTIBODIES
US8993731B2 (en) 2010-03-11 2015-03-31 Ucb Biopharma Sprl PD-1 antibody
EP2609118B1 (en) 2010-08-23 2017-01-18 Board Of Regents, The University Of Texas System Anti-ox40 antibodies and methods of using the same
EP2918607B1 (en) 2010-09-21 2017-11-08 Altor BioScience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
CA2805361A1 (en) 2010-09-29 2012-04-05 Universite De Liege Combination of an agonistic anti-cd40 monoclonal antibody or a cd40 ligand and inactivated or attenuated bacteria for use in the treatment and/or prevention of mastitis
GB201103955D0 (en) 2011-03-09 2011-04-20 Antitope Ltd Antibodies
MX341076B (es) 2011-03-31 2016-08-04 Merck Sharp & Dohme Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
CA3019531A1 (en) 2011-04-19 2012-10-26 Pfizer Inc. Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer
DK2699264T3 (en) 2011-04-20 2018-06-25 Medimmune Llc ANTIBODIES AND OTHER MOLECULES BINDING B7-H1 AND PD-1
EP2537933A1 (en) * 2011-06-24 2012-12-26 Institut National de la Santé et de la Recherche Médicale (INSERM) An IL-15 and IL-15Ralpha sushi domain based immunocytokines
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
AU2012299421B2 (en) 2011-08-23 2016-02-04 Board Of Regents, The University Of Texas System Anti-OX40 antibodies and methods of using the same
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
WO2014066527A2 (en) 2012-10-24 2014-05-01 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
EP4032540A1 (en) 2013-04-19 2022-07-27 Cytune Pharma Cytokine derived treatment with reduced vascular leak syndrome
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
HUE057917T2 (hu) 2014-01-15 2022-06-28 Kadmon Corp Llc Immunmodulátor szerek

Also Published As

Publication number Publication date
ES2963591T3 (es) 2024-04-01
HUE057598T2 (hu) 2022-05-28
CN105612175A (zh) 2016-05-25
JP2016532693A (ja) 2016-10-20
KR102564207B1 (ko) 2023-08-10
AU2014304931A9 (en) 2016-06-16
BR112016002614A2 (pt) 2017-09-12
WO2015018528A1 (en) 2015-02-12
JP2020072726A (ja) 2020-05-14
PL3030575T3 (pl) 2018-12-31
EP3030575A1 (en) 2016-06-15
JP6951479B2 (ja) 2021-10-20
KR20160042922A (ko) 2016-04-20
DK3030575T3 (en) 2018-10-22
BR112016002614B1 (pt) 2023-10-03
DK3444271T3 (da) 2022-01-10
PT3030575T (pt) 2018-10-31
SI3030575T1 (sl) 2018-11-30
US11273204B2 (en) 2022-03-15
AU2014304931B2 (en) 2018-05-10
EP3444271B1 (en) 2021-10-06
MX2016001555A (es) 2016-08-03
JP6649254B2 (ja) 2020-02-19
ES2690046T3 (es) 2018-11-19
CA2919725A1 (en) 2015-02-12
KR102364523B1 (ko) 2022-02-18
HRP20181472T1 (hr) 2018-11-02
WO2015018528A8 (en) 2016-04-07
US20160175459A1 (en) 2016-06-23
EP3995507C0 (en) 2023-10-04
EA201690333A1 (ru) 2016-06-30
HUE064280T2 (hu) 2024-03-28
US20220193199A1 (en) 2022-06-23
PL3995507T3 (pl) 2024-03-04
EP3444271A1 (en) 2019-02-20
PT3444271T (pt) 2022-01-05
BR112016002614A8 (pt) 2022-11-08
EP4269441A3 (en) 2024-01-24
HRP20231437T1 (hr) 2024-02-16
EP3995507B1 (en) 2023-10-04
CA2919725C (en) 2023-04-18
ES2902589T3 (es) 2022-03-29
KR20220025923A (ko) 2022-03-03
BR112016002614B8 (pt) 2023-10-03
EP3030575B1 (en) 2018-07-11
EP3995507A1 (en) 2022-05-11
CN105612175B (zh) 2023-05-09
EP4269441A2 (en) 2023-11-01
EA031080B1 (ru) 2018-11-30
PL3444271T3 (pl) 2022-03-07
AU2014304931A1 (en) 2016-02-25
SI3444271T1 (sl) 2022-03-31

Similar Documents

Publication Publication Date Title
HRP20212023T1 (hr) Modulokini temeljeni na il-15 i il-15ralpha sushi domeni
JP2016532693A5 (hr)
US11723971B2 (en) Antibodies to TIGIT
JP2016527286A5 (hr)
US20220162317A1 (en) Anti-CD112R Compositions and Methods
HRP20201156T1 (hr) Zajednički laki lanci i postupci primjene
HRP20192098T1 (hr) Antitijela na glukokortikoidom inducirani receptor faktora nekroze tumora (gitr) i njihove primjene
FI3303396T3 (fi) Vasta-aineita ox40:ää vastaan ja niiden käyttöjä
JP2016539096A5 (hr)
RU2017117596A (ru) Связывающие молекулы, специфичные в отношении CD73, и пути их применения
HRP20220649T1 (hr) Novi bispecifični format pogodan za upotrebu u visokopropusnom skriningu
KR20180075689A (ko) 키메라 항원 수용체에 관한 방법 및 조성물
WO2014089169A4 (en) Immunotherapy with binding agents
JP2017527272A5 (hr)
HRP20221284T1 (hr) Anti-pvrig antitijela i postupci uporabe
JP2018513172A (ja) がんおよび感染症を処置する際に使用するための免疫チェックポイントモジュレーターの阻害剤
JP2017519494A (ja) Ｏｘ４０ｌ融合タンパク質およびその使用
FI3421486T3 (fi) Uusia vista-ig-rakenteita ja vista-ig:n käyttö autoimmuuni-, allergia- ja tulehdushäiriöiden hoitamiseksi
JP7303391B2 (ja) バイアス型ｉｌ２ムテイン、方法、および組成物
AU2021284273A1 (en) Antibodies to TIGIT
US20220298212A1 (en) Recombinant 4-1bb binding proteins and their use
CN108463246A (zh) 使用人生长分化因子15(gdf-15)抑制剂和免疫检查点阻断剂的联合治疗
Häsler et al. VNAR single-domain antibodies specific for BAFF inhibit B cell development by molecular mimicry
BR112021000396A2 (pt) Moléculas de ligação a mesotelina e cd137
CA3179348A1 (en) Antibodies to nkp46 and constructs thereof for treatment of cancers and infections